High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
774.35M
+10.74%
0.066
-213.77%
796.69M
+12.42%
0.143
-212.01%
820.79M
+15.05%
0.203
-437.78%
Estimates Revision
The market is revising Upward the revenue expectations for Exact Sciences Corporation (EXAS) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 12.59%.
Revenue Estimates for FY2025
Revise Upward
+1.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-21.73%
In Past 3 Month
Stock Price
Go Up
+12.59%
In Past 3 Month
19 Analyst Rating
0Wall Street analysts forecast EXAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 69.94 USD with a low forecast of 54.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
1 Hold
0 Sell
Strong Buy
0Current: 53.020
Low
54.00
Averages
69.94
High
90.00
0Current: 53.020
Low
54.00
Averages
69.94
High
90.00
Guggenheim
Subbu Nambi
Strong Buy
Reiterates
$60
2025-04-11
Reason
Guggenheim
Subbu Nambi
Price Target
$60
2025-04-11
Reiterates
Strong Buy
Reason
Barclays
Luke Sergott
Buy
Maintains
$65 → $55
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$65 → $55
2025-04-10
Maintains
Buy
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Exact Sciences to $55 from $65 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Mizuho
Anthony Petrone
Buy
Initiates
$60
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$60
2025-04-10
Initiates
Buy
Reason
Mizuho initiated coverage of Exact Sciences with an Outperform rating and $60 price target.
RBC Capital
Gerard Cassidy
Hold
Initiates
$52
2025-03-13
Reason
RBC Capital
Gerard Cassidy
Price Target
$52
2025-03-13
Initiates
Hold
Reason
RBC Capital initiated coverage of Exact Sciences with a Sector Perform rating and $52 price target while launching coverage of the Liquid Biopsy space. Exact is the leader in colorectal cancer with its at-home test, Cologuard, the analyst noted. While it has had success displacing traditional screening methods for CRC, new competitive entrants are likely to dampen Exact's growth going forward and the stool-based testing method does not transfer over to other areas of cancer testing so the firm contends that it is unclear if the company will have success with its upcoming product launches.
Piper Sandler
David Westenberg
Buy
Maintains
$75 → $70
2025-02-26
Reason
Piper Sandler
David Westenberg
Price Target
$75 → $70
2025-02-26
Maintains
Buy
Reason
Piper Sandler lowered the firm's price target on Exact Sciences to $70 from $75 following quarterly results. The firm keeps an Overweight rating on the shares.
Scotiabank
Sung Ji Nam
Buy
Maintains
$70 → $73
2025-02-24
Reason
Scotiabank
Sung Ji Nam
Price Target
$70 → $73
2025-02-24
Maintains
Buy
Reason
Scotiabank raised the firm's price target on Exact Sciences to $73 from $70 and keeps an Outperform rating on the shares. Exact's Q4 was in line with the January 12 preannouncement, and the company ended FY24 slightly below initial guide provided last year, the analyst tells investors in a research note. The firm thinks Exact is strongly positioned competitively, based on clinical data presented so far, as well as its extensive commercial channels leveraging ExactNexus.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Exact Sciences Corp (EXAS.O) is 103.11, compared to its 5-year average forward P/E of -69.10. For a more detailed relative valuation and DCF analysis to assess Exact Sciences Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-69.10
Current PE
103.11
Overvalued PE
47.94
Undervalued PE
-186.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
6.28
Current EV/EBITDA
25.30
Overvalued EV/EBITDA
124.26
Undervalued EV/EBITDA
-111.69
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
6.04
Current PS
3.23
Overvalued PS
9.14
Undervalued PS
2.94
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 614.09% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
EXAS News & Events
Events Timeline
(ET)
2025-05-28
06:09:45
Exact Sciences to present new positive data on Oncodetect in colorectal cancer
2025-05-01 (ET)
2025-05-01
16:15:31
Exact Sciences raises FY25 revenue view to $3.07B-$3.12B, consensus $3.06B
2025-05-01
16:14:40
Exact Sciences reports Q1 EPS (54c) vs (60c) last year
Sign Up For More Events
Sign Up For More Events
News
Preview
5.0
06-17NASDAQ.COMInsider Sale: Director at $EXAS Sells 3,207 Shares
Preview
2.0
06-10NASDAQ.COMEXACT Sciences (EXAS) Shares Cross Above 200 DMA
Preview
4.5
06-09NASDAQ.COMNoteworthy ETF Inflows: XBI, EXAS, NBIX, NTRA
Sign Up For More News
People Also Watch
FAQ
What is Exact Sciences Corp (EXAS) stock price today?
What is Exact Sciences Corp (EXAS)'s business?
What is the price predicton of EXAS Stock?
What is Exact Sciences Corp (EXAS)'s revenue for the last quarter?
What is Exact Sciences Corp (EXAS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Exact Sciences Corp (EXAS)'s fundamentals?
How many employees does Exact Sciences Corp (EXAS). have?